Erik Janssen

Erick Janssen is the Global Head of Neurology Patient Relevant Innovative Solutions at UCB, a Belgian based international pharmaceutical company who are world leaders in the field of epilepsy research and medicine development. During a career spanning more than 20 years Erik has held a number of senior leadership roles and responsibilities at country, regional, and international levels, where he has embraced new and creative approaches to delivering value to patients.
Erik joined UCB in 2005. He has held multiple strategic and operational roles within the company including leading the global lifecycle team for UCB’s first anti-epilepsy drug, Keppra, and heading UCB’s Neurology franchise in Germany. Before joining UCB, Erik was a Business Unit Director for Oncology at Sanofi Aventis, where he built a significant record of accomplishments in international sales and marketing.
In his current role, Erik leads an international Mission whose focus is on investigating technology solutions with potential to make a meaningful difference to the lives of people living with neurological conditions like epilepsy and Parkinson’s Disease.
Erik holds a master’s degree in chemistry from the University of Leuven, Belgium. and has a passion for creativity, innovation, healthcare, diversity, culture, sports and photography. His ambition is to inspire and invite people to collaborate and develop effective solutions for people who face the consequences of living with diseases that significantly impact their lives.